Johnson & Johnson: PharmaVitae Profile

Publication Date	July 2009
Publisher	Datamonitor
Product Type	Report
Pages	108
ISBN Number	not applicable
Product Code	DAT04351

Buy this product or for assistance call +44 20 7060 7474

PDF £3,425.00$5697 | €3833

PRINT £3,485.00$5797 | €3901

FAX Order above formats by FAX

Summary

Introduction

This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Johnson & Johnson's performance against key rivals in the prescription pharmaceutical sector
Analyze how J&J will implement life cycle management strategies across its portfolio as a means to combat patent expiries and generic competition
Assess J&J's diverse healthcare offering and how this will act to maintain operating profit growth despite a forecast decline in Rx drug revenue

Content

ABOUT DATAMONITOR HEALTHCARE
About the PharmaVitae team
Chapter 1 About this profile
- PharmaVitae Explorer database
Chapter structure
- Executive summary
- Quarterly news update
- Company introduction
- Company sales
- Company financials
- Key products and competitors
- Data sourcing
- Sales data
- Analyst consensus
Chapter 2 Executive summary
- Key findings
- Prescription pharmaceutical sales and growth rate performance, 2002-14
- Financial performance, 2002-14
- Johnson & Johnson: PharmaVitae forecasts at a glance
- Strategic insight
- Managing the boom & bust of 'blockbuster' drugs
- US small molecule drug sales increase generic exposure
- Lifecycle management will minimize loss from key products
- Pipelines in a product-critical for growth to be maintained
- Despite challenges, J&J's outlook appears robust
- Performance to 2014 will be clear by 2010
- Diversified business balances risk
- Wide range of strategic options to seek growth
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Table of figures
Chapter 3 Quarterly news update
- Key findings
- Product developments
- Deals and alliances
- Product deals
- Technology deals
- M&A activity
- Company announcements
- Future product milestones
Chapter 4 Company introduction
- Key findings
- Background
- Key corporate developments
- M&A history
- M&A strategy
- Current corporate structure
Chapter 5 Company sales
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 2002-14
- Product analysis
- Product analysis, 2002-08
- Product analysis, 2008-14
- Therapy area analysis
- Geographic analysis
- Launch/core/expiry analysis
- Explanation of launch/core/expiry analysis
- Launch analysis, 2008-14
- Core analysis, 2008-14
- Expiry analysis, 2008-14
- Generics analysis, 2008-14
- Molecule type analysis
- Externalization analysis
Chapter 6 Company financials
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
- Operating costs and profit analysis
- Operating costs and profit analysis, 2002-08
- Operating cost ratio and profit margin analysis, 2002-08
- Operating cost ratio and profit margin analysis, 2008-14
- Operating costs and profit analysis, 2008-14
Chapter 7 Key products and competitors
- Key findings
- Overview
- Central nervous system
- Risperdal franchise
- Overview
- Sales forecast
- Success driven by first to market and favorable side effect profile
- US generics hit Risperdal sales from June 2008
- Additional products aimed at retaining patients within JNJ's portfolio
- Invega franchise
- Overview
- Sales forecast
- Limited switching from Risperdal
- Invega Sustenna will build upon Risperdal Consta's success
- Topamax
- Overview
- Sales forecast
- Sales growth has been supported by use in further indications
- Generics set to erode key US market across 2008-09
- Immunology & inflammation
- Remicade
- Overview
- Sales forecast
- J&J markets Remicade in the US only
- Humira has slowed growth of Remicade sales
- New launches will maintain the growth of J&J's I&I franchise
- Simponi (golimumab)
- Overview
- Sales forecast
- Stelara (ustekinumab)
- Overview
- Sales forecast
- Oncology
- Velcade
- Overview
- Sales forecast
- Growth driven by label expansion
- Takeda prevented J&J from acquiring Millennium
- Procrit
- Overview
- Sales forecast
- Decline as market share lost to Aranesp from 2002
- Safety concerns have hit the wider ESA market
- Further competition limited to ex-US markets for now
- Cardiovascular
- Xarelto
- Overview
- Sales forecast
- US launch forecast in 2009
- Set to revolutionize anticoagulant management
- Attractive product profile ensures market success
- Regulatory hurdles remain
- Infectious diseases
- Prezista
- Overview
- Sales forecast
- Growth strengthened by earlier use
- Close fit with additional HIV products
Chapter 8 Appendix
- R&D pipeline
- Remicade sales reconciliation
- References
- Abbreviations
- Exchange rates
- About Datamonitor
- About Datamonitor Healthcare
- Datamonitor consulting
- Disclaimer
- Table 1: Johnson & Johnson - PharmaVitae forecasts at a glance
- Table 2: Johnson & Johnson key product developments, Q1-Q2 2009
- Table 3: Johnson & Johnson product deals and alliances, Q1-Q2 2009
- Table 4: Johnson & Johnson technology deals and alliances, Q1-Q2 2009
- Table 5: Johnson & Johnson M&A activity, Q1-Q2 2009
- Table 6: Johnson & Johnson company announcements, Q1-Q2 2009
- Table 7: Johnson & Johnson future product milestones, 2009-10
- Table 8: Johnson & Johnson product portfolio overview ($m), 2002-08
- Table 9: Johnson & Johnson product portfolio overview ($m), 2008-14
- Table 10: Johnson & Johnson prescription pharmaceutical sales by therapy area ($m), 2008-14
- Table 11: Johnson & Johnson prescription pharmaceutical sales by geographic region ($m), 2008-14
- Table 12: Johnson & Johnson launch portfolio overview ($m), 2008-14
- Table 13: Johnson & Johnson core portfolio overview ($m), 2008-14
- Table 14: Johnson & Johnson expiry portfolio overview ($m), 2008-14
- Table 15: Johnson & Johnson generics portfolio overview ($m), 2008-14
- Table 16: Johnson & Johnson prescription pharmaceutical sales by molecule type ($m), 2008-14
- Table 17: Johnson & Johnson prescription pharmaceutical sales by source ($m), 2008-14
- Table 18: Total Johnson & Johnson sales by business unit ($m), 2002-08
- Table 19: Johnson & Johnson operating revenue/cost analysis ($m), 2002-08
- Table 20: Johnson & Johnson operating cost ratio analysis (% of total revenues), 2002-08
- Table 21: Johnson & Johnson operating cost ratio analysis (% of total revenues), 2008-14
- Table 22: Johnson & Johnson operating revenue/cost analysis ($m), 2008-14
- Table 23: Key products overview
- Table 24: Risperdal: overview
- Table 25: Risperdal franchise: sales forecast ($m), 2008-14
- Table 26: Invega: overview
- Table 27: Invega franchise: sales forecast ($m), 2008-14
- Table 28: Topamax: overview
- Table 29: Topamax: sales forecast ($m), 2008-14
- Table 30: Remicade: overview
- Table 31: Remicade: sales forecast ($m), 2008-14
- Table 32: Simponi: overview
- Table 33: Simponi: sales forecast ($m), 2008-14
- Table 34: Stelara: overview
- Table 35: Stelara: sales forecast ($m), 2008-14
- Table 36: Velcade: overview
- Table 37: Velcade: sales forecast ($m), 2008-14
- Table 38: Procrit: overview
- Table 39: Procrit: sales forecast ($m), 2008-14
- Table 40: Xarelto: overview
- Table 41: Xarelto: sales forecast ($m), 2008-14
- Table 42: Prezista: overview
- Table 43: Prezista: sales forecast ($m), 2008-14
- Table 44: Johnson & Johnson's R&D pipeline (Phase I-registration)
- Table 45: Total Remicade sales forecast ($m), 2008-14
- Table 46: Exchange rates, 2009
List of Figures
- Figure 1: The PharmaVitae Explorer
- Figure 2: Johnson & Johnson prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
- Figure 3: Johnson & Johnson's financial performance ($m), 2002-14
- Figure 4: Lifecycle management strategies boost key J&J franchises, 2002-14 ($m)
- Figure 5: Johnson & Johnson prescription pharmaceutical sales by stage, 2002-14 ($m)
- Figure 6: J&J's strategic options for growth
- Figure 7: Johnson & Johnson SWOT analysis
- Figure 8: Recent & major M&A/ divestment activity, J&J
- Figure 9: Current corporate structure
- Figure 10: Johnson & Johnson prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
- Figure 11: Key product sales ($m), 2002-14
- Figure 12: Johnson & Johnson key sales growth drivers and resistors ($m), 2002-08
- Figure 13: Johnson & Johnson key sales growth drivers and resistors ($m), 2008-14
- Figure 14: Johnson & Johnson prescription pharmaceutical sales by therapy area ($m), 2002-14
- Figure 15: Johnson & Johnson prescription pharmaceutical sales by geographic region ($m), 2002-14
- Figure 16: Johnson & Johnson launch/core/expiry configuration ($m), 2008-14
- Figure 17: Johnson & Johnson prescription pharmaceutical sales by molecule type ($m), 2002-14
- Figure 18: Johnson & Johnson prescription pharmaceutical sales by source ($m), 2002-14
- Figure 19: Johnson & Johnson operating revenue/cost analysis ($m), 2002-14